The need of radiotherapy optimization for glioblastomas considering immune responses

Nishioka, Kentaro; Takahashi, Shuhei; Mori, Takashi; Uchinami, Yusuke; Yamaguchi, Shigeru; Kinoshita, Manabu; Yamashina, Masaaki; Higaki, Hajime; Maebayashi, Katsuya; Aoyama, Hidefumi

The need of radiotherapy optimization for glioblastomas considering immune responses

Nishioka, Kentaro; Takahashi, Shuhei; Mori, Takashi et al.

Japanese Journal of Radiology, 2023, 41(10), 1062-1071

Permalink : https://hdl.handle.net/2115/88980

このアイテムのアクセス数:433件（2026-01-22 21:43 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
Nishioka et al. 2023 - The need of radiotherapy optimization for glioblastomas considering immune responses	pdf	545 KB	2,031

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/88980
タイトル	The need of radiotherapy optimization for glioblastomas considering immune responses
著者	Nishioka, Kentaro ; Takahashi, Shuhei ; Mori, Takashi ; Uchinami, Yusuke ; Yamaguchi, Shigeru ; Kinoshita, Manabu ; Yamashina, Masaaki ; Higaki, Hajime ; Maebayashi, Katsuya ; Aoyama, Hidefumi
e-Rad_Researcher 80463743 著者名 Nishioka, Kentaro
著者名 Takahashi, Shuhei
著者名 Mori, Takashi
著者名 Uchinami, Yusuke
著者名 Yamaguchi, Shigeru
著者名 Kinoshita, Manabu
著者名 Yamashina, Masaaki
著者名 Higaki, Hajime
著者名 Maebayashi, Katsuya
e-Rad_Researcher 80360915 著者名 Aoyama, Hidefumi
言語	英語
キーワード	Glioblastoma
	Radiotherapy
	Target definitions
	Immunotherapy
	Lymphopenia
発行日	2023-10-01
出版者	Springer
収録物名	Japanese Journal of Radiology
巻(号)	41(10)
ページ	1062-1071
抄録	Glioblastoma is the most common of malignant primary brain tumors and one of the tumors with the poorest prognosis for which the overall survival rate has not significantly improved despite recent advances in treatment techniques and therapeutic drugs. Since the emergence of immune checkpoint inhibitors, the immune response to tumors has attracted increasing attention. Treatments affecting the immune system have been attempted for various tumors, including glioblastomas, but little has been shown to be effective. It has been found that the reason for this is that glioblastomas have a high ability to evade attacks from the immune system, and that the lymphocyte depletion associated with treatment can reduce its immune function. Currently, research to elucidate the resistance of glioblastomas to the immune system and development of new immunotherapies are being vigorously carried out. Targeting of radiation therapy for glioblastomas varies among guidelines and clinical trials. Based on early reports, target definitions with wide margins are common, but there are also reports that narrowing the margins does not make a significant difference in treatment outcome. It has also been suggested that a large number of lymphocytes in the blood are irradiated by the irradiation treatment to a wide area in a large number of fractionations, which may reduce the immune function, and the blood is being recognized as an organ at risk. Recently, a randomized phase II trial comparing two types of target definition in radiotherapy for glioblastomas was conducted, and it was reported that the overall survival and progression-free survival were significantly better in a small irradiation field group. We review recent findings on the immune response and the immunotherapy to glioblastomas and the novel role of radiotherapy and propose the need to develop an optimal radiotherapy that takes radiation effects on the immune function into account.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	1867-1071
EISSN	1867-108X
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1007/s11604-023-01434-x